Skip to main content

Regulus Therapeutics(RGLS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

PR Newswire - Thu Aug 11, 2022

IND accepted and first subject dosed in the Phase 1 Single-Ascending Dose (SAD) study of RGLS8429for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe